BiotechTube
Paratus Sciences

Paratus Sciences

New York, United States· Est.
paratussciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $100M

Overview

Paratus Sciences is an early-stage, private biotech pioneering a novel drug discovery approach inspired by bat biology. The company has announced its first development candidate, PS-1001, for immunology and inflammation, indicating progression from platform validation to program advancement. Backed by strategic partnerships and a world-class team, Paratus aims to translate the exceptional disease resistance and metabolic traits of bats into a new class of human therapeutics. Its success hinges on validating its unique platform and advancing its pipeline through clinical development.

Immunology & InflammationCardiometabolic

Technology Platform

Proprietary discovery platform that merges genomics and informatics to study bat DNA, transcriptomics, and physiology. It identifies evolutionary adaptations in bats related to immunity, inflammation, and metabolism to uncover novel therapeutic targets for human diseases.

Funding History

1
Total raised:$100M
Series A$100M

Opportunities

The platform taps into a unique and underexplored biological niche (bat adaptations) to potentially discover first-in-class therapeutics with novel mechanisms of action.
Large addressable markets in immunology/inflammation and cardiometabolic diseases provide significant commercial potential for successful candidates.
Strategic partnerships with research institutions and larger pharma companies offer avenues for validation, funding, and development capabilities.

Risk Factors

High translational risk that bat biology will not yield safe and effective human therapeutics.
Platform risk that the discovery engine fails to generate a sustainable pipeline of druggable targets.
Financial and execution risk as a pre-revenue, early-stage company dependent on investor funding to navigate the costly and failure-prone drug development pathway.

Competitive Landscape

Paratus operates in a highly specialized niche with few, if any, direct competitors focused exclusively on bat-inspired drug discovery. However, it competes indirectly with all biopharma companies pursuing novel mechanisms in immunology and cardiometabolism. Its competitive edge lies in its unique source of biological insight and first-mover advantage in systematically mining bat genomics for therapeutic applications.

More companies in Small Molecule Drugs →More companies in United States →